首页> 外文期刊>American Journal of Physiology >Retention of human bone marrow-derived cells in murine lungs following bleomycin-induced lung injury.
【24h】

Retention of human bone marrow-derived cells in murine lungs following bleomycin-induced lung injury.

机译:博来霉素诱导的肺损伤后鼠肺中人骨髓来源细胞的保留。

获取原文
获取原文并翻译 | 示例
           

摘要

We studied the capacity of adult human bone marrow-derived cells (BMDC) to incorporate into distal lung of immunodeficient mice following lung injury. Immunodeficient NOD/SCID and NOD/SCID/beta(2) microglobulin (beta(2)M)(null) mice were administered bleomycin (bleo) or saline intranasally. One, 2, 3 and 4 days after bleo or saline, human BMDC labeled with CellTracker Green CMFDA (5-chloromethylfluorescein diacetate) were infused intravenously. Retention of CMFDA(+) cells was maximal when delivered 4 days after bleo treatment. Seven days after bleo, <0.005% of enzymatically dispersed lung cells from NOD/SCID mice were CMFDA(+), which increased 10- to 100-fold in NOD/SCID/beta(2)M(null) mice. Preincubation of BMDC with Diprotin A, a reversible inhibitor of CD26 peptidase activity that enhances the stromal-derived factor-1 (SDF-1/CXCL12)/CXCR4 axis, resulted in a 30% increase in the percentage of CMFDA(+) cells retained in the lung. These data indicate that human BMDC can be identified in lungs of mice following injury, albeit at low levels, and this may be modestly enhanced by manipulation of the SDF-1/CXCR4 axis. Given the overall low number of human cells detected, methods to increase homing and retention of adult BMDC, and consideration of other stem cell populations, will likely be required to facilitate engraftment in the treatment of lung injury.
机译:我们研究了成年人类骨髓源性细胞(BMDC)掺入肺损伤后免疫缺陷小鼠远端肺的能力。免疫缺陷的NOD / SCID和NOD / SCID / beta(2)微球蛋白(beta(2)M)(null)小鼠经鼻腔施用博来霉素(bleo)或生理盐水。出血或生理盐水后1、2、3和4天,将静脉注射CellCeller Green CMFDA(5-氯甲基荧光素二乙酸酯)标记的人BMDC。漂白处理后4天交付时,CMFDA(+)细胞的保留量最大。出血后7天,来自NOD / SCID小鼠的酶分散的肺细胞<0.005%为CMFDA(+),在NOD / SCID / beta(2)M(null)小鼠中增加10到100倍。 BMDC与Diprotin A的预孵育,Diprotin A是可逆的CD26肽酶活性抑制剂,可增强基质衍生因子-1(SDF-1 / CXCL12)/ CXCR4轴,导致保留的CMFDA(+)细胞百分比增加了30%在肺里。这些数据表明,人BMDC可以在损伤后的小鼠肺中被鉴定出来,尽管含量很低,并且可以通过操纵SDF-1 / CXCR4轴来适当增强。考虑到检测到的人类细胞总数很少,可能需要采用方法来增加成年BMDC的归巢和保留,并考虑其他干细胞的数量,以促进移植治疗肺损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号